Saturday, June 25, 2022 9:40:26 AM
Your reading of the methylated MGMT data is misguided. That statistically significant separation was not from having slightly more methylated, the separation was from the methylated MGMT doing substantially better than the ECA methylated MGMT. It is quite remarkable DCVax-l still trended better in unmethylated as well — particularly at the beginning and end of the tail. You then need to combine this outcome with the recurrent, where the only two trials in the ECA that came clean with a comprehensive MGMT analysis, had more, not less mgmt than DCVax-l, the other ECAs conveniently skipped comprehensive MGMT analysis despite all having newer trials and testing capability than DCVax-l, and yet DCVax-l still doubled median survival in recurrent compared to ECA trials, and the gap of survival increased over time.
KPS over 80, not over 90 is a prognostic indicator for survival. The slight difference of 5% more over 90 in the ECA nGBM group can’t begin to explain the consistent statistically significant difference in the survival curve.
Most strikingly, the differences in very long term survival cannot be explained by the slight differences. In both nGBM and rGBM, the survival gap increases substantially over time. For gosh sake Jerry, the ECAs had a pool of 1366 patients to begin with, and none were proven to be alive (beating heartbeats) at five years. They relied exclusively on censoring lost to follow up and gimmicks to achieve 5.7% five year survival.
Whereas, in comparison, DCVax-l started with only 232 patients, and still had 25 at risk (beating heartbeats) and even without using censorship had nearly 11% alive and with censorship 13% alive at five years. I really can’t help you Jerry if you don’t get this. Where are the beating heartbeats in the ECA at five years Jerry? Where are they?
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM